Cargando…
Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome
In clinical practice, few prostate cancer (PCa) patients are associated with metabolic syndrome (MetS), while few others acquire MetS during treatment. Whether the treatment of PCa increases the occurrence of MetS remains to be confirmed. This study reviewed the changes in MetS patients before and a...
Autores principales: | Chen, Zongping, Deng, Jichun, Yan, Yong, Li, Min, Chen, Chanjuan, Chen, Chao, Zhao, Sicong, Song, Tao, Liu, Tong, Wen, Xin, Yao, Yuhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061238/ https://www.ncbi.nlm.nih.gov/pubmed/29948970 http://dx.doi.org/10.1007/s12672-018-0335-8 |
Ejemplares similares
-
GSTT1, an increased risk factor for prostate cancer in patients with metabolic syndrome
por: Liu, Dongdong, et al.
Publicado: (2022) -
Metabolic Syndrome Components are Associated with Increased Prostate Cancer Risk
por: Zhang, Jian-Qin, et al.
Publicado: (2015) -
The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence
por: Xiang, Yu-zhu, et al.
Publicado: (2013) -
The Impact of Metabolic Syndrome and Type 2 Diabetes Mellitus on Prostate Cancer
por: Sousa, André P., et al.
Publicado: (2022) -
Metabolic syndrome and metastatic prostate cancer correlation study, a real-world study in a prostate cancer clinical research center, Xinjiang, China
por: An, Hengqing, et al.
Publicado: (2022)